Opioid Blister Pack Mandate Could Be Phased-In Based On Prescription Volume
Executive Summary
US FDA seeks public input on potential advantages and challenges of requiring 5-, 10, and -15-count blister packs for certain opioids and the idea of staggering implementation.
You may also be interested in...
Woodcock Highlights US FDA Opioid Plans Amid Sen. Manchin And Others’ Criticisms
The statement outlining opioid priorities in the FDA’s FY 2022 budget request comes on the heels of Sen. Manchin’s criticism of the acting commissioner and FDA opioid policy.
Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun
Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?
US FDA Needs ‘More Streamlined’ REMS Enforcement Authority, Inspector General Says
Additional power would allow the agency to punish 'simple' REMS violations and improve administration of risk management programs, according to a new report looking at FDA's oversight of opioids.